{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:27:43Z","timestamp":1791836863137,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the feasibility of streamlining radioembolization using yttrium-90 resin microspheres without lung shunt fraction (LSF) assessment in patients with colorectal liver metastases (mCRC)\u2009&lt;\u20097\u00a0cm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 32 patients with mCRC who underwent radioembolization between June 2021 and April 2025. Eligibility criteria were: primary target tumor\u2009&lt;\u20097\u00a0cm, the sum of the diameters of the two largest tumors\u2009\u2264\u200910\u00a0cm, treatment with resin microspheres, omission of LSF measurement, and at least one follow-up imaging study. Radiation activity was prescribed based on tumor location, liver function, and clinical setting, using both single-compartment and multi-compartment dosimetry with assumption of a LSF of 5% and tumor-to-normal (TN) ratio of 3. Post-treatment Y-90 PET\/CT dosimetry was performed in 15 patients. Clinical outcomes, tumor response, and treatment-related toxicity were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median administered radiation activity was 0.50\u00a0GBq (IQR, 0.41\u20130.82). Median mean absorbed dose (mAD) to the perfused tissue was 136\u00a0Gy, and median tumor absorbed dose (TAD) was 347\u00a0Gy with assumption of TN ratio of 3. Post-treatment PET\/CT analysis (n\u2009=\u200915) showed a median TAD of 432\u00a0Gy with a median TN ratio of 3.9, and lung dose derived from Y-90 PET\/CT image ranged from 0.12 to 0.61\u00a0Gy. The best tumor responses were complete response in 12.5%, partial response in 59.4%, and stable disease in 28.1%. One- and two-year local tumor progression-free survival rates were 70.8% and 54.1%, respectively. No patient developed radiation pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Streamlining radioembolization without LSF assessment appears feasible for patients with mCRC\u2009&lt;\u20097\u00a0cm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-01984-w","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:02:01Z","timestamp":1775804521000},"page":"1459-1467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility study of streamlining radioembolization with yttrium-90 resin microspheres without lung shunt fraction measurement for colorectal liver metastasis\u2009&lt;\u20097\u00a0cm"],"prefix":"10.1007","volume":"44","author":[{"given":"Myungsu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Chul","family":"Paeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minseok","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6016-247X","authenticated-orcid":false,"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"1","key":"1984_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1\u201315.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1984_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.220387","volume":"305","author":"EC Emmons","year":"2022","unstructured":"Emmons EC, Bishay S, Du L, Krebs H, Gandhi RT, Collins ZS, et al. Survival and toxicities after (90)Y transarterial radioembolization of metastatic colorectal cancer in the RESIN registry. Radiology. 2022;305(1):228\u201336.","journal-title":"Radiology"},{"issue":"9","key":"1984_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159\u201371.","journal-title":"Lancet Oncol"},{"issue":"39","key":"1984_CR4","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"10","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;10(39):3897\u2013907.","journal-title":"J Clin Oncol"},{"key":"1984_CR5","first-page":"293","volume":"24","author":"S Ho","year":"1997","unstructured":"Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293\u20138.","journal-title":"Eur J Nucl Med"},{"issue":"6","key":"1984_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jhep.2020.02.024","volume":"72","author":"A Gabr","year":"2020","unstructured":"Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, et al. Streamlining radioembolization in UNOS T1\/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72(6):1151\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"1984_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jvir.2024.10.007","volume":"36","author":"HC Kim","year":"2025","unstructured":"Kim HC, Suh M, Paeng JC, Lee JH, Lee M, Chung JW, et al. Streamlining radioembolization without lung shunt estimation versus regular radioembolization in patients with hepatocellular carcinoma within the Milan criteria. J Vasc Interv Radiol. 2025;36(1):78-87.e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1984_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18697-5","volume":"12","author":"TW Choi","year":"2022","unstructured":"Choi TW, Joo I, Kim HC. Association of dysmorphic intratumoral vessel with high lung shunt fraction in patients with hepatocellular carcinoma. Sci Rep. 2022;12(1):14248.","journal-title":"Sci Rep"},{"key":"1984_CR9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jvir.2025.05.027","volume":"36","author":"HC Kim","year":"2025","unstructured":"Kim HC, Kim DH, Suh M, Paeng J, Choi JW. High-dose radioembolization limited by lung shunt for hepatocellular carcinoma supplied by the inferior phrenic artery. J Vasc Interv Radiol. 2025;36:1427\u201335.","journal-title":"J Vasc Interv Radiol"},{"key":"1984_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jvir.2025.08.028","volume":"36","author":"HC Kim","year":"2025","unstructured":"Kim HC, Suh M, Paeng JC, Choi JW. Same-day versus multiday planning\/treatment radioembolization with yttrium-90 resin microspheres in patients with liver cancer \u2265 5 cm. J Vasc Interv Radiol. 2025;36:2010\u201320.","journal-title":"J Vasc Interv Radiol"},{"key":"1984_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.977160","volume":"13","author":"HC Kim","year":"2023","unstructured":"Kim HC, Kim GM. Radiation pneumonitis following Yttrium-90 radioembolization: a Korean multicenter study. Front Oncol. 2023;13:977160.","journal-title":"Front Oncol"},{"key":"1984_CR12","unstructured":"National Cancer Institutie. Common terminology criteria for adverse events. Version 5.0. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed April 27; 2021."},{"issue":"3","key":"1984_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/hep.29207","volume":"66","author":"B Sangro","year":"2017","unstructured":"Sangro B, Mart\u00ednez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology. 2017;66(3):969\u201382.","journal-title":"Hepatology"},{"issue":"2","key":"1984_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1984_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jvir.2024.08.031","volume":"36","author":"B Kis","year":"2025","unstructured":"Kis B, Gyano M. Radiation pneumonitis after Yttrium-90 radioembolization: a systematic review. J Vasc Interv Radiol. 2025;36(2):207\u201318.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1984_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2025.09.006","volume":"37","author":"MA Thomas","year":"2026","unstructured":"Thomas MA, Alamuri T, Lee RC, Giardina D, Karageorgiou J, Mani N, et al. Modeling clinical relevance and risk in Yttrium-90 radioembolization of the liver: lung shunt fraction variability according to imaging modality, cancer type, and tumor size. J Vasc Interv Radiol. 2026;37(1):107834.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"1984_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/MNM.0000000000001089","volume":"40","author":"M Elsayed","year":"2019","unstructured":"Elsayed M, Martin JG, Dabrowiecki A, Goldman DT, Faraj R, McMahon JT, et al. Tc-99m-MAA lung shunt fraction before Y-90 radioembolization is low among patients with non-hepatocellular carcinoma malignancies. Nucl Med Commun. 2019;40(11):1154\u20137.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"1984_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00330-016-4345-z","volume":"27","author":"TF Jakobs","year":"2017","unstructured":"Jakobs TF, Paprottka KJ, Rae\u00dfler F, Strobl F, Lehner S, Ilhan H, et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol. 2017;27(1):113\u20139.","journal-title":"Eur Radiol"},{"issue":"3","key":"1984_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2214\/AJR.06.0707","volume":"188","author":"FH Miller","year":"2007","unstructured":"Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol. 2007;188(3):776\u201383.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"1984_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.26223","volume":"123","author":"SA Padia","year":"2021","unstructured":"Padia SA, Johnson GE, Agopian VG, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172\u20138.","journal-title":"J Surg Oncol"},{"issue":"2","key":"1984_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/RLU.0000000000005565","volume":"50","author":"PM Dimopoulos","year":"2025","unstructured":"Dimopoulos PM, Sotirchos VS, Dunne-Jaffe C, Petre EN, Gonen M, Zhao K, et al. Voxel-based dosimetry predicts local tumor progression post 90 Y radiation segmentectomy of colorectal liver metastases. Clin Nucl Med. 2025;50(2):133\u201342.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"1984_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.jvir.2023.08.031","volume":"34","author":"PW Doyle","year":"2023","unstructured":"Doyle PW, Workman CS, Shah N, McGonigle TW, Grice JV, Huang S, et al. Predictive partition dosimetry and outcomes after Yttrium-90 resin microsphere radioembolization of colorectal cancer metastatic to the liver: a retrospective analysis. J Vasc Interv Radiol. 2023;34(12):2138\u201346.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1984_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jvir.2023.09.023","volume":"35","author":"CP Brunson","year":"2024","unstructured":"Brunson CP, McGregor HJ, Hennemeyer CT, Patel MV, Woodhead GJ, Young SJ. Measurement of the tumor-to-normal ratio for radioembolization of hepatocellular carcinoma: a prospective study comparing 2-dimensional perfusion angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT\/CT. J Vasc Interv Radiol. 2024;35(1):94\u2013101.","journal-title":"J Vasc Interv Radiol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01984-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01984-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01984-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:08:56Z","timestamp":1784866136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01984-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01984-w","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hyo-Cheol Kim has received honoraria from Boston Scientific, SIRTEX, and Guerbet, along with research funds and travel support from SIRTEX. The other authors have no conflicts of interest to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Seoul National University Hospital (2412\u2013093-1596).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}